PridCor Therapeutics LLC, a clinical-stage biopharmaceutical company, today announced the acquisition of a global antiviral ...

As part of its strategy for COVID-19 therapeutics, the European Commission (EC) on Tuesday released a portfolio of the initial five therapeutics being considered for authorization for the treatment of ...

Once known mainly for COVID-19 vaccines, mRNA technology is now being adapted for cancer, cardiovascular, autoimmune, and rare genetic diseases. Advances in nanocarriers, AI-driven delivery design, ...

ModeX Therapeutics Inc., an OPKO Health company (NASDAQ: OPK), today announced that the first participants have been dosed in a Phase 1 clinical trial evaluating MDX2301 for the prevention of COVID-19 ...

PRIDCor Therapeutics Granted Global Development and Commercialization License for IMC-1 and IMC-2 Assets for All Indications, ...

As the world rolls into year 2 of the COVID-19 pandemic, regulators and drug developers are grappling with how to address variant strains of SARS-CoV-2 as they bud and expand globally. The inevitable ...

PridCor Therapeutics LLC, a clinical-stage biopharmaceutical company, today announced the acquisition of a global antiviral asset portfolio, establishing the Company as a ...

Health and care staff played an instrumental role in the “extraordinary feat” of delivering covid vaccinations in the UK that ...